[Anabolic therapy in osteoporosis--part 1].
Osteoporosis is one of the most important problems in developed societies. Unfortunately, all drugs available nowadays on the market exhibit antiresorptive action bringing only moderate benefits to patients suffering from this disease. For the last few years, the number of studies on the suggested use of anabolic therapy in the treatment of osteoporosis has been growing up. In the present study we describe in details sodium fluoride, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), growth hormone, insulin-like growth factor I, and parathormone and its analogues, describing their mechanism of action and adverse effects. We also show the results of experimental studies and clinical trials in which the mentioned drugs were used. On the basis of available results we are trying to establish the exact position of anabolic agents in pharmacotherapy of osteoporosis.
Okopień
Bogusław
B
Zakład Farmakologii Klinicznej Slaskiej Akademii Medycznej, Katowice.
Krysiak
Robert
R
Labuzek
Krzysztof
K
Herman
Zbigniew Stanisław
ZS
D019382:Human Growth Hormone / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000494:pharmacology*; D012969:Sodium Fluoride / Q000494:pharmacology*; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010281:Parathyroid Hormone; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D012969:Sodium Fluoride